Skip to Main Content
DownloadHi-Res Photo

Danielle Antin-Ozerkis, MD

Associate Professor of Medicine (Pulmonary)

Contact Information

Danielle Antin-Ozerkis, MD

Office Locations

Mailing Address

  • Pulmonary, Critical Care & Sleep Medicine

    PO Box 208057, 15 York Street

    New Haven, CT, 06520-8057

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

As part of a comprehensive approach to patient care, Yale ILD offers clinical drug trials for patients with IPF and other forms of pulmonary fibrosis. I am the primary investigator at Yale for these studies. I participate in the Center’s translational research program which is aimed at understanding the mechanisms of pulmonary fibrosis development and progression.

Coauthors

Selected Publications

  • A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY: Learning From the Past, Looking to the Future.Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE, Chupp G, Cohn L, Dela Cruz CS, Ferrante LE, Herzog EL, Koff J, Rochester CL, Ryu C, Singh I, Tickoo M, Winks V, Gulati M, Possick JD. A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY: Learning From the Past, Looking to the Future. Chest 2021, 159:949-958.
  • Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials.Wuyts W, Antin-Ozerkis D, Huggins JT, LaCamera PP, Spagnolo P, Vašáková M, Wijsenbeek MS, Polman B, Kirchgaessler KU, Scholand MB. Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respiratory Medicine 2019, 150:120-125.
  • Update in Pulmonary Fibrosis 2018.Sgalla G, Kulkarni T, Antin-Ozerkis D, Thannickal VJ, Richeldi L. Update in Pulmonary Fibrosis 2018. American Journal Of Respiratory And Critical Care Medicine 2019, 200:292-300.
  • Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. The Lancet. Respiratory Medicine 2019, 7:657-664.
  • Connective Tissue Disease-Associated Interstitial Lung Disease: Evaluation and Management.Antin-Ozerkis D, Hinchcliff M. Connective Tissue Disease-Associated Interstitial Lung Disease: Evaluation and Management. Clinics In Chest Medicine 2019, 40:617-636.
  • Thoracic Manifestations of Rheumatic Disease.Antin-Ozerkis D, Highland KB. Thoracic Manifestations of Rheumatic Disease. Clinics In Chest Medicine 2019, 40:xiii.
  • Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA 2018, 319:2299-2307.
  • An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002).Gotfried MH, Girod CE, Antin-Ozerkis D, Burgess T, Strombom I, Stauffer JL, Kirchgaessler KU, Padilla ML. An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002). Pulmonary Therapy 2018, 4:59-71.
  • Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis.Ryu C, Sun H, Gulati M, Herazo-Maya J, Chen Y, Osafo-Addo A, Brandsdorfer C, Winkler J, Blaul C, Faunce J, Pan H, Woolard T, Tzouvelekis A, Antin-Ozerkis DE, Puchalski JT, Slade M, Gonzalez AL, Bogenhagen DF, Kirillov V, Feghali-Bostwick C, Gibson K, Lindell K, Herzog RI, Dela Cruz CS, Mehal W, Kaminski N, Herzog EL, Trujillo G. Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2017, 196:1571-1581.
  • Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.Tzouvelekis A, Herazo-Maya JD, Slade M, Chu JH, Deiuliis G, Ryu C, Li Q, Sakamoto K, Ibarra G, Pan H, Gulati M, Antin-Ozerkis D, Herzog EL, Kaminski N. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology (Carlton, Vic.) 2017, 22:486-493.
  • Interstitial lung disease: time to rethink the snapshot diagnosis?Antin-Ozerkis D, Kolb M. Interstitial lung disease: time to rethink the snapshot diagnosis? Thorax 2016, 71:5-7.
  • Supportive care for patients with pulmonary complications of connective tissue disease.Gulati M, Antin-Ozerkis D. Supportive care for patients with pulmonary complications of connective tissue disease. Seminars In Respiratory And Critical Care Medicine 2014, 35:274-82.
  • Pulmonary complications of connective tissue disease.Antin-Ozerkis D, Swigris J. Pulmonary complications of connective tissue disease. Seminars In Respiratory And Critical Care Medicine 2014, 35:157.
  • Interstitial lung disease in the connective tissue diseases.Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial lung disease in the connective tissue diseases. Clinics In Chest Medicine 2012, 33:123-49.
  • Pulmonary manifestations of rheumatoid arthritis.Antin-Ozerkis D, Evans J, Rubinowitz A, Homer RJ, Matthay RA. Pulmonary manifestations of rheumatoid arthritis. Clinics In Chest Medicine 2010, 31:451-78.
  • Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Laboratory Investigation; A Journal Of Technical Methods And Pathology 2010, 90:812-23.
  • Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2001, 19:2247-53.
  • Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. American Journal Of Human Genetics 2000, 67:841-50.
  • I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer.Nathanson KL, Antin-Ozerkis D, Couch FJ, Weber BL. I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer. American Journal Of Medical Genetics 1999, 85:189-90.
  • The APCI1307K allele and breast cancer risk.Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King MC, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, Offit K. The APCI1307K allele and breast cancer risk. Nature Genetics 1998, 20:13-4.

Clinical Trials

ConditionsStudy Title
Diseases of the LungSaracatinib (AZD0530) in the Treatment of Patients with Idiopathic Pulmonary Fibrosis
Diseases of the Lung; Diseases of the Respiratory SystemsA Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Diseases of the Lung; Diseases of the Respiratory SystemsSafety, Tolerability, Kinetics, and Repeatability of the Novel LPA1 PET Ligand 18F-BMS-986327
Immune SystemPathogenic Wnt-beta catenin target genes in macrophages and fibrosis
Edit Profile